The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial
recent developmental investment and subsequent drug approvals over the past 6 years. In …

Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the
treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 …

ABSTRACT Introduction: Antibody-Drug Conjugates (ADCs) are becoming increasingly
important weapons in the fight against cancer, as evidenced by the growing number of …

Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

The targeted delivery of potent cytotoxic molecules into cancer cells is considered a
promising anticancer strategy. The design of clinically effective antibody–drug conjugates …